Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis

摘要

Human leukocyte antigen (HLA) alleles are implicated in drug-induced hypersensitivity, including by nevirapine and abacavir. The purpose of this meta-analysis was to evaluate the relationship between HLA polymorphisms and hypersensitivity to antiretroviral therapy in human immunodeficiency virus (HIV)-infected patients. We conducted a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library for studies that evaluated the associations of HLA polymorphisms with antiretroviral therapy-induced hypersensitivity published in April 2019. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were considered as estimates of the effect. The meta-analysis included 17 studies that assessed a total of 4273 patients. First, carriers of HLA-A *24 were associated with an increased risk of hypersensitivity among patients with HIV who received antiretroviral therapy (OR: 12.12; P?=?0.018). Second, five SNPs of HLA-B genotypes, including *18 (OR: 1.63; P?=?0.028), *35 (OR: 2.31; P?=?0.002), *39 (OR: 11.85; P?=?0.040), *51 (OR: 1.66; P?=?0.028), and *81 (OR: 8.11; P?=?0.021), were associated with an increased risk of hypersensitivity. Conversely, carriers of HLA-B *15 were associated with a reduced risk of hypersensitivity (OR: 0.43; P??0.001). Third, HLA-C *04 was associated with an increased risk of hypersensitivity (OR: 3.09; P??0.001), whereas a lower risk for hypersensitivity was observed in patients who were carriers of HLA-C *02 (OR: 0.22; P?=?0.030), *03 (OR: 0.53; P?=?0.049), and *07 (OR: 0.61; P?=?0.044). Finally, carriers of HLA-DRB1 *05 (OR: 0.18; P?=?0.006) and *15 (OR: 0.23; P?=?0.013) were associated with a reduced risk of hypersensitivity among patients receiving antiretroviral therapy. The findings of this meta-analysis indicated patients carrying HLA-A *24, HLA-B *18, *35, *39, *51, *81, HLA-C *04 were associated with a higher risk of hypersensitivity. Conversely, subjects carrying HLA-B *15, HLA-C *02, *03, *07, HLA-DRB1 *05, *15 were associated with a reduced risk of hypersensitivity.